Aileron Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Director Josef H. von Rickenbach acquired 47,060 shares of Rein Therapeutics, Inc. common stock through open market purchases.
Rein Therapeutics, Inc. reports that President and CEO James Brian Windsor acquired shares in a follow-on offering and was granted stock options.
Voss Capital and affiliated entities increased their beneficial ownership in Rein Therapeutics, Inc. by acquiring 104,183 shares of common stock.
Voss Capital, a 10% owner and director, significantly expanded its beneficial ownership in Rein Therapeutics, Inc. through recent common stock purchases.
Rein Therapeutics, Inc. Director Manuel Aivado was granted 17,500 stock options with an exercise price of $1.55, vesting fully by July 2026.
Rein Therapeutics, Inc. Director Josef H. von Rickenbach was granted 17,500 stock options with an exercise price of $1.55 per share, vesting by July 2026.
Rein Therapeutics, Inc. Director Alan A. Musso was granted 17,500 stock options with an exercise price of $1.55, vesting by July 2026.
Rein Therapeutics Director William Fairey received a grant of 17,500 stock options with an exercise price of $1.55, vesting by July 2026.
Rein Therapeutics, Inc. Director and 10% Owner Reinhard J. Ambros was granted 17,500 stock options with an exercise price of $1.55 per share.
Aileron Therapeutics' CEO, James Brian Windsor, indirectly acquired shares of common stock through his son on December 5, 2024.
Aileron Therapeutics director Manuel Aivado was granted 35,000 stock options on December 2, 2024, which will vest on December 2, 2025.
Aileron Therapeutics director Reinhard J. Ambros was granted 35,000 stock options on December 2, 2024, which will vest on December 2, 2025.
Director William Fairey of Aileron Therapeutics was granted 35,000 stock options on December 2, 2024, which will vest on December 2, 2025.
Director Josef H. von Rickenbach of Aileron Therapeutics acquired 35,000 stock options on December 2, 2024, which vest on December 2, 2025.
Aileron Therapeutics director Alan Musso was granted 35,000 stock options on December 2, 2024, which will vest on December 2, 2025.
Aileron Therapeutics' CEO, James Brian Windsor, was granted 517,500 stock options on December 2, 2024, according to a recent SEC filing.
Manuel Aivado, a director of Aileron Therapeutics, Inc., was granted stock options to purchase 2,725 shares of common stock on August 20, 2024.
Director Josef H. von Rickenbach reports the grant of a stock option for Aileron Therapeutics shares.
Director William Fairey of Aileron Therapeutics acquired stock options on August 20, 2024, as reported in a Form 4 filing with the SEC.
Reinhard J. Ambros, a director of Aileron Therapeutics, acquired stock options exercisable for 2,725 shares of common stock.
Director Alan A. Musso of Aileron Therapeutics, Inc. acquired stock options on August 20, 2024.
Form 4: University of Texas/Texas A&M Investment Management Co. Reduces Stake in Aileron Therapeutics
The University of Texas/Texas A&M Investment Management Co. has decreased its holdings in Aileron Therapeutics through recent stock sales.
Form 4: University of Texas/Texas A&M Investment Management Co. Reduces Stake in Aileron Therapeutics
The University of Texas/Texas A&M Investment Management Co. has decreased its holdings in Aileron Therapeutics through a series of sales between June 10 and June 12, 2024.
Form 4: University of Texas/Texas A&M Investment Management Co. Reduces Stake in Aileron Therapeutics
The University of Texas/Texas A&M Investment Management Co. has reported selling shares of Aileron Therapeutics, Inc. in a series of transactions between June 5th and June 7th, 2024.
The University of Texas/Texas A&M Investment Management Company filed an amended Form 4 to correct errors in a previous filing regarding sales of Aileron Therapeutics (ALRN) common stock.
The University of Texas Investment Management Company reports selling shares of Aileron Therapeutics (ALRN) between April 29, 2024, and May 1, 2024, reducing its holdings.
Josef H. von Rickenbach, a director of Aileron Therapeutics, filed an amended SEC Form 4 to correct the exercise price of stock options granted on February 28, 2024.
Reinhard J. Ambros, a director of Aileron Therapeutics, filed an amended SEC Form 4 to correct the exercise price of stock options granted on February 28, 2024.
James Brian Windsor, President and COO of Aileron Therapeutics, reports the conversion of Series X Preferred Stock into common stock and the disposal of 2,000 common stock shares on March 5, 2024.
Director Reinhard J. Ambros of Aileron Therapeutics, Inc. was granted stock options on February 28, 2024, according to a Form 4 filing with the SEC.